0001179110-22-002416.txt : 20220325 0001179110-22-002416.hdr.sgml : 20220325 20220325170920 ACCESSION NUMBER: 0001179110-22-002416 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220324 FILED AS OF DATE: 20220325 DATE AS OF CHANGE: 20220325 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stewart Jeffrey Ryan CENTRAL INDEX KEY: 0001761675 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 22772330 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 edgar.xml FORM 4 - X0306 4 2022-03-24 0 0001551152 AbbVie Inc. ABBV 0001761675 Stewart Jeffrey Ryan 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 0 1 0 0 EVP, Chief Commercial Officer Common Stock, $0.01 par value 2022-03-24 4 M 0 27690 58.88 A 88631 D Common Stock, $0.01 par value 2022-03-24 4 S 0 27690 159.2046 D 60941 D Common Stock, $0.01 par value 1338 I By spouse in trust Option (Right to Buy) 58.88 2022-03-24 4 M 0 27690 58.88 D 2016-02-19 2025-02-18 Common Stock 27690 0 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.86 to $159.55 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reporting person disclaims beneficial ownership of all securities held by his spouse. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c). Steven L. Scrogham, attorney-in-fact for Jeffrey R. Stewart 2022-03-25